Duplicating biologics is infinitely much more complex than duplicating the traditional drug compounds. I say MNTA's chances of being successful duplicating the biologics they have chosen is not very good, I reckon. I believe there was an article in the WSJ that supports this thesis.
The above is unquestionable. Biologics is a whole new ballgame, and I expect it will be a much larger firm that can "copy" a biologic. We do need pioneers that can start the process, however.